key: cord-0034755-iawcsntb authors: Chen, Yi-Ning; Wu, Ching Ching; Lin, Tsang Long title: Virus Neutralization Assay for Turkey Coronavirus Infection date: 2015-09-10 journal: Animal Coronaviruses DOI: 10.1007/978-1-4939-3414-0_3 sha: 1f91399656745ff094d50a364a03f687866f9447 doc_id: 34755 cord_uid: iawcsntb Turkey coronavirus (TCoV) infection induces the production of protective antibodies against the sequent exposure of TCoV. Serological tests to determine TCoV-specific antibodies are critical to evaluate previous exposure to TCoV in the turkey flocks and differentiate serotypes from different isolates or strains. A specific virus neutralization assay using embryonated turkey eggs and immunofluorescent antibody assay for determining TCoV-specific neutralizing antibodies is described in this chapter. Virus neutralization titer of turkey serum from turkeys infected with TCoV is the dilution of serum that can inhibit TCoV infection in 50 % of embryonated turkey eggs. Virus neutralization assay for TCoV is useful to monitor the immune status of turkey flocks infected with TCoV for the control of the disease. Turkey coronavirus (TCoV) causes atrophic enteritis in turkeys and belongs to species Avian coronavirus of the genus Gammacoronavirus in the family Coronaviridae . The most closely related coronavirus is infectious bronchitis virus (IBV) causing respiratory disease in chickens. Turkey coronavirus infection induced protective antibody responses because turkeys that survived the infection did not develop clinical signs and TCoV was not detected in their intestines and feces after subsequent exposure to TCoV [ 1 , 2 ] . Therefore, serological tests can be used to detect previous exposure to TCoV and differentiate the serotypes or strains from different isolates. The TCoV-specifi c antibodies can be detected by either enzymelinked immunosorbent assay ( ELISA ) using TCoV S protein [ 3 , 4 ] , TCoV N protein [ 5 , 6 ] , or IBV virions [ 7 ] or immunofl uorescent antibody ( IFA ) assay using intestine sections containing TCoV [ 8 ] . Among different serological tests, virus neutralization ( VN ) assay is the most specifi c test showing the inhibition of viral infection to target host tissues or cells by protective neutralizing antibodies. Without cell culture system available for TCoV, embryonated turkey eggs are used for VN assay of TCoV. Because TCoV infection usually does not cause embryonic death, IFA assay [ 4 , 8 ] or realtime RT-PCR [ 9 ] is used to detect TCoV in the intestines of turkey embryos to determine whether or not turkey embryos are infected by TCoV. In this chapter, a protocol for VN assay is described for determining the VN titer of serum from turkeys infected with TCoV or receiving experimental vaccines against TCoV infection. In step 1 , TCoV stock and serum to be tested are diluted and incubated for neutralization reaction. In step 2 , the mixture of TCoV and serum is inoculated into embryonated turkey eggs. In step 3 , the infection of TCoV is determined by the detection of TCoV in the intestines of turkey embryos using IFA assay. In step 4 , VN titer, the dilution of serum that can inhibit TCoV infection in 50 % of inoculated embryonated turkey eggs, is calculated according to the results of IFA assay [ 4 , 10 ] . 4. Take eggs to a darkroom because this procedure requires illumination of the egg with an egg candling device while being inoculated. 5 . Drill a small hole through the eggshell at the point near the back and head of embryo above the line that separates air cell and the rest of egg. 2. Open the shell via the air cell. 3. Pull the turkey embryo out, and then break the neck quickly. 4. Separate the yolk sac gently. 5. Open the abdominal cavity, and cut the connective tissue between stomach and intestine . Gently separate gall bladder and spleen from intestine. 6. Cut the cloaca and remove the whole intestine from abdomen. 7. Arrange the intestine loop together as a circle and place the intestine in the Whirl-Pak bag (Thermo Fisher Scientifi c). Snap freeze the intestines in dry ice and store at −80 °C freezer later. 8. Cut frozen intestine sections using the cryotome (TBS Minotome Plus™) and place the sections onto the glass slides. 9. Fix the sections in acetone for 10 min at room temperature (RT). 10. Add 50-100 μL of 2 % goat serum diluted with PBS to each section and incubate at RT for 30 min. 11. Dip slides into ddH 2 O and wash slides with PBS with stirring for 10 min. 12. Dip slides into ddH 2 O and get rid of excess water. Leave the slides to air-dry till almost dry. 13. Add 50-100 μL of 1:40 anti-TCoV serum diluted with PBS to each section and incubate at RT for 1 h. 14. Dip slides into ddH 2 O and wash slides with PBS with stirring for 15 min. TCoV in the TCoV-containing intestine homogenate. The infectivity unit of TCoV is the 50 % embryo infectious dose or EID 50 . One EID 50 unit is the amount of virus that will infect 50 % of virus-inoculated embryonated eggs. Immunofl uorescence antibody assay is used to determine the number of turkey embryos infected with TCoV. Example for calculating virus infectivity titer is illustrated below. According to the results of IFA assay, the number of TCoV-infected or non-infected eggs, the accumulated number of TCoV-infected, non-infected, or tested eggs, and the infection percentage of eggs inoculated with tenfold serially diluted TCoV can be calculated ( Table 1 ) . The index is calculated by the infection percentage: Index = [(% Infected at dilution immediately above 50 %) − 50 %]/[(% Infected at dilution immediately above 50 %) − (% Infected at dilution immediately below 50 %)] % infected at dilution immediately above 50 %: 10 −3 → 62.5 % % infected at dilution immediately below 50 %: 10 −4 → 25 % Index = (62.5 % − 50 %)/(62.5 % − 25 %) = 12.5 %/37.5 % = 0.33. The index is then applied to the dilution that produced the percentage infected immediately above 50 %. In this example is the 10 −3 dilution. The index of 0.33 is applied to this dilution. In this example, the dilution that provided the 50 % infection of eggs or 1 EID 50 is 10 −3.33 . The reciprocal of this dilution is the amount of virus contained in the 0.2 mL of the original suspension = 10 3.33 EID 50 /0.2 mL = 5 × 10 3.33 EID 50 /mL = 1.05 × 10 4 EID 50 / mL. Thus, the infectivity titer of TCoV has been calculated to be 1.05 × 10 4 EID 50 /mL. so it is very fragile and sensitive to the process of freezing and thawing. It is recommended to use −80 or −20 °C preequilibrated CoolBox™ (VWR, Batavia, IL, USA) to transport virus vials from −80 °C freezer to laboratory before dilution and inoculation. Serum sample A is used for VN titer calculation. Anti-TCoV serum is used as a positive control serum. Both serum A and anti-TCoV serum are diluted into 1:4, 1:16, and 1:64, respectively. Infection of TCoV in the embryonated eggs is determined by IFA assay. The number of TCoV-infected or non-infected eggs, the accumulated number of TCoV-infected, non-infected, or tested eggs, and the infection percentage of eggs inoculated with tenfold serially diluted TCoV can be calculated ( Table 2 ). The index is calculated by the neutralization percentage: Index = [(% Neutralized at dilution immediately above 50 %) − 50 %]/[(% Neutralized at dilution immediately above 50 %) − (%Neutralization at dilution immediately below 50 %)]. 1. For anti-TCoV serum, % neutralized at dilution immediately above 50 % is 85.7 % and the dilution is 4 −2 ; % neutralized at dilution immediately below 50 % is 33.3 % and the dilution is 4 −3 . Therefore, the index is (85.7 % − 50 %)/ (85.7 % − 33.3 %) = 0.68. The index is then applied to the dilution that produced the percentage neutralized immediately above 50 %, which is 4 −2 dilution. For anti-TCoV serum, the dilution that can provide 50 % neutralization of TCoV on the infection of turkey embryo is 4 −2.68 . Therefore, the VN titer of anti-TCoV serum is 1:41. 2. For serum A, % neutralized at dilution immediately above 50 % is 71.4 % and the dilution is 4 −1 ; % neutralized at dilution immediately below 50 % is 28.6 % and the dilution is 4 −2 . Therefore, the index is (71.4 % − 50 %)/(71.4 % − 28.6 %) = 0.5. The index is then applied to the dilution that produced the percentage neutralized immediately above 50 %, which is 4 −1 dilution. For serum A, the dilution that can provide 50 % neutralization of TCoV on the infection of turkey embryo is 4 −1.5 . Therefore, the VN titer of anti-TCoV serum is 1:8. 3. In conclusion, anti-TCoV serum has higher VN titer of 1:41 than the VN titer of serum A, which is 1:8. Triangle Biomedical Systems (TBS) FITC-conjugated goat anti-turkey IgG (H + L) antibody (KPL Humoral and cellular immune responses in turkey poults infected with turkey coronavirus Seroprevalence of turkey coronavirus in North American turkeys determined by a newly developed enzyme-linked immunosorbent assay based on recombinant antigen Use of recombinant S1 spike polypeptide to develop a TCoV-specifi c antibody ELISA Identifi cation and characterization of a neutralizing-epitopecontaining spike protein fragment in turkey coronavirus Expression and purifi cation of turkey coronavirus nucleocapsid protein in Escherichia coli Recombinant nucleocapsid protein-based enzyme-linked immunosorbent assay for detection of antibody to turkey coronavirus Detection of antibody to turkey coronavirus by antibodycapture enzyme-linked immunosorbent assay utilizing infectious bronchitis virus antigen Immunofl uorescent studies on localization of secretory immunoglobulins in the intestines of turkeys recovered from turkey coronaviral enteritis Emergence of a group 3 coronavirus through recombination A laboratory manual for the isolation, identifi cation and characterization of avian pathogens, 5th edn The protocol " Virus neutralization assay for turkey coronavirus infection " illustrated in this chapter had been successfully carried out in the authors' studies on molecular virology, immunology, and/or vaccinology of turkey coronavirus and its related viral enteritis . Those studies had been in part fi nancially supported by USDA, North Carolina Poultry Federation, and/or Indiana Department of Agriculture and technically assisted by Drs. Tom Brien and David Hermes, Mr. Tom Hooper, and Ms. Donna Schrader for clinical serology, virus isolation and propagation, and animal experimentation.